QIAGEN signs Global Supply Agreement
Aug 02 2004

QIAGEN signs Global Supply Agreement

Venlo, The Netherlands, August 02, 2004 - QIAGEN N.V. (NASDAQ: QGENF; Frankfurt, Prime Standard: QIA) the global leader of nucleic acid purification and handling technologies today announced that it has entered into a global supply agreement with NOVARTIS PHARMA AG (NYSE: NVS), a world leader in pharmaceuticals and consumer health based in Switzerland. Under the terms of this agreement QIAGEN will act as a global supplier for consumable products for nucleic acid stabilisation, separation, purification and handling, nucleic acid amplification, as well as automated instrumentation, siRNA products and related services. Financial terms were not disclosed.

QIAGEN's position as the world's leading provider of products and services for separating, purifying and handling nucleic acids is based on a broad range of proprietary technologies which are the basis for a portfolio which addresses more than 80 different applications in nucleic acid handling, separation and purification. By combining innovative sample collection and stabilization products with sample preparation and analysis technologies on automated platforms, QIAGEN provides robust and integrated solutions for a wide range of different molecular biology applications such as RT-PCR, quantitative PCR, microarray analysis and gene silencing.

"We are pleased that Novartis has chosen QIAGEN as a global supplier of laboratory goods and services for molecular biology research experiments ", said Vincent Sigrist, General Manager of QIAGEN ( Switzerland ) AG. "This global supply contract allows QIAGEN an even more efficient servicing of this important customer. Robust and efficient extraction and purification of target nucleic acid is key to the sensitivity and reliability of analysis technologies such as PCR, microarray analysis and gene silencing. QIAGEN's state-of-the-art technologies in nucleic acid separation, purification and handling as well as its innovative integrated solutions guarantee increasing reliability, speed, and ease-of-use of molecular biology techniques, and are significant key benefits to speed up drug development processes."

 

About QIAGEN

QIAGEN N.V., a Netherlands holding company with subsidiaries in Germany , the United States , Japan , the United Kingdom , Switzerland , France , Italy , Australia , Norway , Austria and Canada , believes it is the world's leading provider of innovative enabling technologies and products for the separation, purification and handling of nucleic acids. The Company has developed a comprehensive portfolio of more than 320 proprietary, consumable products for nucleic acid separation, purification and handling, nucleic acid amplification, as well as automated instrumentation, synthetic nucleic acid products and related services. QIAGEN's products are sold in more than 42 countries throughout the world to academic research markets and to leading pharmaceutical and biotechnology companies. In addition, the Company is positioning its products for sale into developing commercial markets, including DNA sequencing and genomics, nucleic acid-based molecular diagnostics, and genetic vaccination and gene therapy. QIAGEN employs approximately 1,400 people worldwide. Further information on QIAGEN can be found at http://www.qiagen.com/.

 

 

Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products and markets and operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations and risks of dependency on logistics), variability of operating results, the commercial development of the DNA sequencing, genomics and synthetic nucleic acid-related markets, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's, products (including seasonal fluctuations), difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate its products from competitors, and the integration of acquisitions of technologies and businesses. For further information, refer to the discussion in reports that QIAGEN has filed with the U.S. Securities and Exchange Commission (SEC).

 

Contact:


IR QIAGEN N.V.
Tel.: +49 2103 29 11710
Fax +49 2103 29 21710
Email ir@qiagen.com
SOCIAL SHARING

Share this page